New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
10:53 EDTSTAA, ICPT, JASO, GESOptions with decreasing implied volatility: STAA ICPT JASO RSX GES
News For STAA;ICPT;JASO;GES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
07:08 EDTJASOUBS to hold meetings at Solar Power International
Meetings at Solar Power International are being held in Las Vegas on October 21-23.
October 20, 2014
07:16 EDTSTAAAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
October 15, 2014
09:21 EDTICPTIntercept pullback a buying opportunity, says Summer Street
Subscribe for More Information
07:24 EDTICPTIntercept management to meet with Deutsche Bank
Subscribe for More Information
October 14, 2014
06:42 EDTJASOPV modules with solar-grade wafers to account for 89% of capacity, DigiTimes says
Solarbuzz says solar photovoltaic modules using solar-grade wafers will account for 89% of solar capacity forecast to be installed in 2014, reports DigiTimes. Thin-filmed panel makers will supply nearly 8% of end-market demand in 2014, while premium cyrstalline silicon suppliers making up the remaining 3% share. Publicly traded companies in the space include Canadian Solar (CSIQ), First Solar (FSLR), JA Solar (JASO), SunPower (SPWR), Trina Solar (TSL), Panasonic (PCRFY) and Yingli Green Energy (YGE). Reference Link
October 9, 2014
09:03 EDTICPTIntercept pullback a buying opportunity, says Summer Street
Subscribe for More Information
October 8, 2014
12:42 EDTICPTIntercept weakness a buying opportunity, says Wedbush
Subscribe for More Information
12:11 EDTICPTIntercept management to meet with Oppenheimer
Subscribe for More Information
09:20 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
07:05 EDTICPTIntercept says FLINT trial NASH data will not be presented at AASLD
Intercept Pharmaceuticals announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases, or AASLD, Annual Meeting, being held in Boston, Massachusetts from November 7-11. Obeticholic acid, or OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor in development for primary biliary cirrhosis, nonalcoholic steatohepatitis, primary sclerosing cholangitis and other chronic liver and intestinal diseases. CEO Mark Pruzanski said, "We are pleased that several key abstracts from Intercept's Phase 3 program for OCA in PBC will be presented at AASLD. With respect to the NIDDK-sponsored FLINT trial of OCA in NASH, we have learned that the NASH CRN has decided to focus on finalizing the manuscript intended for near term publication in lieu of presentation at AASLD. We are reaffirming the previously reported top-line results based on a revised draft manuscript that our partners at NIDDK have provided us. We believe that peer reviewed publication of the FLINT data will mark another important milestone supportive of OCA's potential as a novel therapy for patients with NASH and associated liver fibrosis. In the meantime, we continue preparing for the initiation of our Phase 3 NASH program in the first half of 2015."
October 7, 2014
10:02 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:32 EDTICPTIntercept initiated with an Outperform at JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use